198 related articles for article (PubMed ID: 1976450)
1. Characterization of an etoposide-resistant human small-cell lung cancer cell line.
Minato K; Kanzawa F; Nishio K; Nakagawa K; Fujiwara Y; Saijo N
Cancer Chemother Pharmacol; 1990; 26(5):313-7. PubMed ID: 1976450
[TBL] [Abstract][Full Text] [Related]
2. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
[TBL] [Abstract][Full Text] [Related]
3. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
[TBL] [Abstract][Full Text] [Related]
4. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
5. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
6. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
8. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
Nokihara H; Yano S; Nishioka Y; Hanibuchi M; Higasida T; Tsuruo T; Sone S
Jpn J Cancer Res; 2001 Jul; 92(7):785-92. PubMed ID: 11473730
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
12. Characterization of an etoposide-resistant human ovarian cancer cell line.
Kubota N; Nishio K; Takeda Y; Ohmori T; Funayama Y; Ogasawara H; Ohira T; Kunikane H; Terashima Y; Saijo N
Cancer Chemother Pharmacol; 1994; 34(3):183-90. PubMed ID: 7911742
[TBL] [Abstract][Full Text] [Related]
13. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of a vindesine-resistant human small-cell lung cancer cell line.
Ohta S; Nishio K; Kubo S; Nishio M; Ohmori T; Takahashi T; Saijo N
Br J Cancer; 1993 Jul; 68(1):74-9. PubMed ID: 8391305
[TBL] [Abstract][Full Text] [Related]
15. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
Takigawa N; Ohnoshi T; Ueoka H; Yonei T; Kiura K; Tabata M; Kodani T; Kamei H; Segawa Y; Shibayama T
Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762
[TBL] [Abstract][Full Text] [Related]
16. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
[TBL] [Abstract][Full Text] [Related]
17. Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.
Evans CD; Mirski SE; Danks MK; Cole SP
Cancer Chemother Pharmacol; 1994; 34(3):242-8. PubMed ID: 8004758
[TBL] [Abstract][Full Text] [Related]
18. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide.
Hosking LK; Whelan RD; Shellard SA; Davies SL; Hickson ID; Danks MK; Hill BT
Int J Cancer; 1994 Apr; 57(2):259-67. PubMed ID: 7908897
[TBL] [Abstract][Full Text] [Related]
19. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
de Jong S; Zijlstra JG; de Vries EG; Mulder NH
Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
